Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation.

BACKGROUND Recently a less invasive method of screening and diagnosing Niemann-Pick C (NP-C) disease has emerged. This approach involves the use of a metabolic screening test (oxysterol assay) instead of the current practice of clinical assessment of patients suspected of NP-C (review of medical history, family history and clinical examination for the signs and symptoms). Our objective is to compare costs and outcomes of plasma oxysterol screening versus current practice in diagnosis of NP-C disease among intellectually disabled (ID) patients using decision-analytic methods. METHODS A discrete event simulation model was conducted to follow ID patients through the diagnosis and treatment of NP-C, forecast the costs and effectiveness for a cohort of ID patients and compare the outcomes and costs in two different arms of the model: plasma oxysterol screening and routine diagnosis procedure (anno 2013) over 5 years of follow up. Data from published sources and clinical trials were used in simulation model. Unit costs and quality-adjusted life-years (QALYs) were discounted at a 3% annual rate in the base case analysis. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS The outcomes of the base case model showed that using plasma oxysterol screening for diagnosis of NP-C disease among ID patients is a dominant strategy. It would result in lower total cost and would slightly improve patients' quality of life. The average amount of cost saving was $3642 CAD and the incremental QALYs per each individual ID patient in oxysterol screening arm versus current practice of diagnosis NP-C was 0.0022 QALYs. Results of sensitivity analysis demonstrated robustness of the outcomes over the wide range of changes in model inputs. CONCLUSION Whilst acknowledging the limitations of this study, we conclude that screening ID children and adolescents with oxysterol tests compared to current practice for the diagnosis of NP-C is a dominant strategy with clinical and economic benefits. The less costly, more sensitive and specific oxysterol test has potential to save costs to the healthcare system while improving patients' quality of life and may be considered as a routine tool in the NP-C diagnosis armamentarium for ID. Further research is needed to elucidate its effectiveness in patients presenting characteristics other than ID in childhood and adolescence.

[1]  A. Akopian Regulation of nociceptive transmission at the periphery via TRPA1-TRPV1 interactions. , 2011, Current pharmaceutical biotechnology.

[2]  Y. Chien,et al.  Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat , 2012, Orphanet Journal of Rare Diseases.

[3]  F. Sedel,et al.  Development of a Suspicion Index to aid diagnosis of Niemann-Pick disease type C , 2012, Neurology.

[4]  M. Patterson,et al.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.

[5]  S. Ashwal,et al.  Evidence Report: Genetic and metabolic testing on children with global developmental delay , 2011, Neurology.

[6]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[7]  W. Pavan,et al.  Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  G. Francis,et al.  The National Niemann–Pick C1 disease database: Report of clinical features and health problems , 2007, American journal of medical genetics. Part A.

[9]  F. Sedel,et al.  Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. , 2012, Molecular genetics and metabolism.

[10]  M. Pineda,et al.  New agents and approaches to treatment in Niemann-Pick type C disease. , 2011, Current pharmaceutical biotechnology.

[11]  D. Ory Niemann-Pick type C: a disorder of cellular cholesterol trafficking. , 2000, Biochimica et biophysica acta.

[12]  Ling-Hsiang Chuang,et al.  Mapping for economic evaluation. , 2012, British medical bulletin.

[13]  C. V. van Karnebeek,et al.  The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. , 2014, Molecular genetics and metabolism.

[14]  R. Hennekam,et al.  Etiology of mental retardation in children referred to a tertiary care center: a prospective study. , 2005, American journal of mental retardation : AJMR.

[15]  N. Baumann,et al.  The adult form of Niemann-Pick disease type C. , 2006, Brain : a journal of neurology.

[16]  C. Doran,et al.  How much does intellectual disability really cost? First estimates for Australia , 2012, Journal of intellectual & developmental disability.

[17]  R. Oostenbrink Diagnostic and prognostic research in paediatrics: Children with meningeal signs , 2001 .

[18]  M. Patterson,et al.  Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. , 2010, Molecular genetics and metabolism.

[19]  Lisa G Shaffer,et al.  Genetic basis of intellectual disability. , 2013, Annual review of medicine.

[20]  J. Caro,et al.  Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.

[21]  M. Patterson,et al.  Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C , 2010, Journal of child neurology.

[22]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[23]  M. O'Callaghan,et al.  Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. , 2010, Molecular genetics and metabolism.

[24]  J. Vance,et al.  Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin , 2014, Journal of Lipid Research.

[25]  W. Henley,et al.  The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. , 2012, Health technology assessment.

[26]  Anneliese O. Speak,et al.  A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma[S] , 2011, Journal of Lipid Research.

[27]  G. Besley,et al.  The natural history of Niemann–Pick disease type C in the UK , 2007, Journal of Inherited Metabolic Disease.

[28]  C. V. van Karnebeek,et al.  The treatable intellectual disability APP www.treatable-id.org: A digital tool to enhance diagnosis & care for rare diseases , 2012, Orphanet Journal of Rare Diseases.

[29]  E. Hunsche,et al.  Cost of illness associated with Niemann-Pick disease type C in the UK , 2009, Journal of medical economics.

[30]  F. Sedel,et al.  Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. , 2009, Molecular genetics and metabolism.

[31]  T. Irie,et al.  Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. , 2013, Molecular genetics and metabolism.

[32]  Marie T. Vanier,et al.  Niemann–Pick disease type C , 2003, Clinical genetics.

[33]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[34]  M. Baumgartner,et al.  Recommendations on the diagnosis and management of Niemann-Pick disease type C. , 2009, Molecular genetics and metabolism.

[35]  O. Amaral,et al.  Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.

[36]  C. Fischer,et al.  Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators , 2013, Orphanet Journal of Rare Diseases.

[37]  D. Balding,et al.  Genetic screening for Niemann–Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study , 2013, Human molecular genetics.